Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03461952
Title Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

Advanced Solid Tumor

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.